Results for postmenopavzi translation from Slovenian to English

odrasle bolnice (ženske v postmenopavzi):
adult (postmenopausal women):

zdravilo conbriza je namenjeno samo ženskam v postmenopavzi.
conbriza is for use only by postmenopausal women.

zdravilo fablyn se uporablja samo pri ženskah v postmenopavzi.
fablyn is only for use in postmenopausal women.

zdravilo fablyn se sme uporabljati samo pri ženskah v postmenopavzi.
fablyn is only for use in postmenopausal women.

zdravilo conbriza je indicirano za uporabo samo pri ženskah v postmenopavzi.
conbriza is only indicated for use in postmenopausal women.

preglednica 2: pogostnost zlomov pri ženskah v postmenopavzi v obdobju 5 let
table 2: fracture incidence in postmenopausal women over 5 years

Ženske v postmenopavzi potrebujejo povprečno po 1.500 mg elementarnega kalcija na dan.
postmenopausal women require an average of 1,500 mg/day of elemental calcium.

najpogostejša vrsta zlomov zaradi osteoporoze pri ženskah v postmenopavzi so vretenčni zlomi.
vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.

farmakokinetiko 20 mg enkratnega odmerka bazedoksifena so ovrednotili v študiji pri 26 zdravih ženskah v postmenopavzi.
the pharmacokinetics of a 20 mg single-dose of bazedoxifene were evaluated in a study in 26 healthy postmenopausal women.

zdravilo fablyn je indicirano za zdravljenje osteoporoze pri ženskah v postmenopavzi z zvečanim tveganjem zloma kosti.
fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

ibandronsko kislino lahko uporabljajo samo ženske v postmenopavzi, ženske v rodni dobi pa ga ne smejo uporabljati.
ibandronic acid is only for use in postmenopausal women and must not be taken by women of child bearing potential.

zdravljenje žensk v postmenopavzi je trajalo 12 mesecev, 124 jih je bilo izpostavljenih zdravilu fablyn, 125 pa placebu.
the duration of treatment in postmenopausal women was 12 months, 124 were exposed to fablyn and 125 were exposed to placebo.

ker se zdravilo fablyn uporablja pri ženskah v postmenopavzi, ni indicirano pri otrocih in mladostnikih, mlajših od 18 let.
there is no indication for fablyn in children and adolescents below 18 years of age since the medicinal product is for use in postmenopausal women only.

histološka analiza biopsij kosti po dveh in treh letih zdravljenja žensk v postmenopavzi je pokazala normalno kakovost kosti in odsotnost motenj mineralizacije.
the histological analysis of bone biopsies after two and three years of treatment of postmenopausal women showed bone of normal quality and no indication of a mineralization defect.

za ocenjevanje kakovosti kosti so odvzeli kostne biopsije 71 ženskam v postmenopavzi, ki so bile vključene v preskušanja bmd, po 2 letih zdravljenja.
to assess bone quality, bone biopsies were obtained from 71 postmenopausal women enrolled in bmd trials after 2 years of treatment.

zdravljenje žensk v postmenopavzi je trajalo 60 mesecev, 2.852 jih je bilo randomiziranih na zdravilo fablyn, 2.852 pa na placebo.
the duration of treatment in postmenopausal women was 60 months, 2,852 were randomized to fablyn and 2,852 were randomized to placebo.

k populacijski farmakokinetični analizi so prispevali farmakokinetični podatki, pridobljeni pri okrog 2.000 ženskah v postmenopavzi, vključno z bolnicami v izbranih kliničnih preskušanjih osteoporoze.
pharmacokinetic data from over 2,000 postmenopausal women including patients in selected osteoporosis clinical trials contributed to a population pharmacokinetic analysis.

vpliv zdravila fablyn na profil lipidov so ovrednotili v 3-letni podštudiji študije pearl; podštudija je zajela 1.014 žensk v postmenopavzi.
the effect of fablyn on the lipid profile was evaluated in a 3-year substudy of the pearl study; the substudy enrolled 1,014 postmenopausal women.

farmakokinetične študije medsebojnega delovanja pri ženskah v postmenopavzi so pokazale, da s tamoksifenom ali hormonskim nadomestnim zdravljenjem (estrogenom) ne prihaja do medsebojnega delovanja.
pharmacokinetic interaction studies in postmenopausal women have demonstrated the absence of any interaction potential with tamoxifen or hormone replacement therapy (oestrogen).

zdravilo duavive je indicirano za uporabo samo pri ženskah v postmenopavzi in ga ženske v rodni dobi ne smejo jemati (glejte poglavji 4.6 in 5.3).
duavive is only indicated for use in postmenopausal women and must not be taken by women of childbearing potential (see sections 4.6 and 5.3).